# Efficacy and Safety of HCP1102 Capsule

> **NCT02552667** · PHASE3 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 228 (actual)

## Conditions studied

- Asthma With Allergic Rhinitis

## Interventions

- **DRUG:** HCP1102+HGP0711Placebo
- **DRUG:** HCP1102Placebo+HGP0711

## Key facts

- **NCT ID:** NCT02552667
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 228 (ACTUAL)
- **Last updated:** 2015-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02552667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02552667, "Efficacy and Safety of HCP1102 Capsule". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02552667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*